期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

miRNAs在三阴性乳腺癌多药耐药性中的研究进展 被引量：5

Research progress of miRNAs in multidrug resistance of triple negative breast cancer
下载PDF
导出
摘要 三阴性乳腺癌作为乳腺恶性肿瘤中最具侵袭性的类型,化学治疗是其主要而有效的治疗手段,但多药耐药性的产生仍是影响疗效的主要障碍。miRNAs是一种内生型的、非编码小RNAs,它作为一种潜在的致瘤因子或抑制因子,能靶向调节其目的基因从而参与肿瘤的耐药。因此,在开拓新的三阴性乳腺癌基因治疗的策略中,miRNAs具有潜在的治疗价值。本文总结了miRNAs在三阴性乳腺癌多药耐药中的作用机制及其在治疗中的应用前景。 Triple-negative breast carcinoma(TNBC) is one of the most aggressive types of breast cancer.Chemotherapy is the main and effective treatment,however,the emergence of multidrug resistance is still the chief obstacle to curative effect.MicroRNAs are endogenously synthesized,small,non-coding RNAs,where they can act as potent oncogenes or tumor suppressors by targeting relative genes involving in cancer chemoresistance.MicroRNAs are,therefore,considered amongst the promising candidates for development of novel therapeutic approaches against TNBC.In this review,we summarized mechanism of action of microRNAs in multidrug resistance(MDR) and promising treatment perspective in TNBC.
作者 邓榆薇 路丹 Deng Yuwei;Lu Dan(Department of Medical Oncology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China.)
机构地区 哈尔滨医科大学附属第二医院肿瘤内科
出处 《现代肿瘤医学》 CAS 2019年第23期4304-4307,共4页 Journal of Modern Oncology
基金 吴阶平医学基金会临床科研专项资助基金(编号:320.6750.17182)
关键词 三阴性乳腺癌 MIRNAS 多药耐药 基因干预 triple-negative breast carcinoma miRNAs multidrug resistance gene interference
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献19

  • 1W a n g H , Tan G , Dong L , et al. Circulating MiR - 125 b as a markerpredicting chemoresistance in breast cancer [J]. P L o S O n e , 2 0 1 2 , 7( 4 ) :e34210.
  • 2C h e n L, Y a n g L, Qiao F, et al. H i g h levels of nucleolar spindle - associatedprotein a n d reduced levels of B R C A 1 expression predict poorprognosis in triple - negative breast cancer [J]. P L o S O n e , 2 0 1 5 ,10( 1 0 ) :e 0 1 4 0 5 7 2 .
  • 3L a B a r g e M A , M o r a - Blanco E L , S a m s o n S, et al. Breast cancer b e yo n d the age of mutation [J] . Gerontology, 2 0 1 6 , 6 2 ( 4 ) :4 3 4 - 4 4 2 .
  • 4Liu Y , Z h u P - W a n g Y , et al. Antimetastatic therapies of the polysulfidediallyl trisulfide against triple - negative breast cancer ( T N B C ) viasuppressing M M P 2 / 9 b y blocking N F - k a p p a B a n d E R K / M A P K signalingp a t h w ays[J]. P L o S O n e , 2 0 1 5 , 1 0 ( 4 ) :e 0 1 2 3 7 8 1 .
  • 5Navratil J, Fabian P - Palacova M , etal. Triple negative breast cancer[J]. Klin Onk o l , 2 0 1 5 , 2 8 ( 6 ) :4 0 5 - 4 1 5 .
  • 60 Reilly E A , G u b b i n s L, S h a r m a S, et al. T h e fate of chemoresistancein triple negative breast cancer ( T N B C ) [J] . B B A Clin, 2 0 1 5 ,3 :2 5 7- 2 7 5 .
  • 7H o f m a n n M H , Heinrich J, Radziwill G , et al. A short hairpin D N A a nalogousto m i R - 1 2 5 b inhibits C - R a f expression, proliferation,a n dsurvival of breast cancer cells[J]. M o l C a n c e r R e s - 2 0 0 9 , 7 ( 1 0 ) : 163 5- 1 6 4 4 .
  • 8Saetrom P , Biesinger J, Li S M , et al. A risk variant in a n m i R - 1 2 5 bbinding site in B M P R 1 B is associated with breast cancer pathogenesis[J]. C a n c e r Re s , 2 0 0 9 , 6 9 ( 1 8 ) :7 4 5 9 - 7 4 6 5 .
  • 9C h e n X , Liu J, F e n g W K , et al. M i R - 1 2 5 b protects against ethanol -i nduced apoptosis in neural crest cells a n d m o u s e e m b r y o s b y targetingB a k 1 a n d P U M A [J] . E x p Neurol, 2 0 1 5 ,271 : 10 4 - 111.
  • 10T a n L ,Y u J T ,Liu Q Y ,et al. Circulating m i R - 1 2 5 b as a biomarker ofAlzheimers disease [J] . J Neurol Sci, 2 0 1 4 , 3 3 6 ( 1 - 2 ) :5 2 - 5 6 .

共引文献5

同被引文献35

引证文献5

二级引证文献6

现代肿瘤医学
2019年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部